Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States

Fu, Alex Z.; Jhaveri, Mehul

doi:10.3111/13696998.2012.673524

Cited by 18 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The magnitude of the overall estimates is smaller than the $42,401 per person annual treatment cost estimate reported by Fu and Jhaveri 18 among a sample of privately insured women aged 18–64 years. There are a number of possible explanations for the differences in the estimates.…”

Section: Discussioncontrasting

confidence: 60%

“…Many breast cancer treatments occur in an outpatient setting such as hormonal therapies, lumpectomy, radiation therapy, and neoadjuvant and adjuvant chemotherapies. 18 …”

Section: Discussionmentioning

confidence: 99%

“…16 This paper reports the costs by type of service and also identifies women in active treatment during the year. Although many studies have focused on the Medicare population 17 and on the privately insured population aged 65 years and younger, 11,18 to the authors’ knowledge, no studies have previously examined breast cancer treatment costs in this younger population.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Medical Care Costs of Breast Cancer in Privately Insured Women Aged 18–44 Years

Allaire

Ekwueme

Guy

et al. 2016

American Journal of Preventive Medicine

View full text Add to dashboard Cite

Introduction Breast cancer in women aged 18–44 years accounts for approximately 27,000 newly diagnosed cases and 3,000 deaths annually. When tumors are diagnosed, they are usually aggressive, resulting in expensive treatment costs. The purpose of this study is to estimate the prevalent medical costs attributable to breast cancer treatment among privately insured younger women. Methods Data from the 2006 MarketScan® database representing claims for privately insured younger women were used. Costs for younger breast cancer patients were compared with a matched sample of younger women without breast cancer, overall and for an active treatment subsample. Analyses were conducted in 2013 with medical care costs expressed in 2012 U.S. dollars. Results Younger women with breast cancer incurred an estimated $19,435 (SE=$415) in additional direct medical care costs per person per year compared with younger women without breast cancer. Outpatient expenditures comprised 94% of the total estimated costs ($18,344 [SE=$396]). Inpatient costs were $43 (SE=$10) higher and prescription drug costs were $1,048 (SE=$64) higher for younger women with breast cancer than in younger women without breast cancer. For women in active treatment, the burden was more than twice as high ($52,542 [SE=$977]). Conclusions These estimates suggest that breast cancer is a costly illness to treat among younger, privately insured women. This underscores the potential financial vulnerability of women in this age group and the importance of health insurance during this time in life.

show abstract

Section: Discussioncontrasting

confidence: 60%

“…Many breast cancer treatments occur in an outpatient setting such as hormonal therapies, lumpectomy, radiation therapy, and neoadjuvant and adjuvant chemotherapies. 18 …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Medical Care Costs of Breast Cancer in Privately Insured Women Aged 18–44 Years

Allaire

Ekwueme

Guy

et al. 2016

American Journal of Preventive Medicine

View full text Add to dashboard Cite

show abstract

“…The estimated total cost associated with GCA in the first year following diagnosis in the US is higher than the first-year cost associated with non-cystic fibrosis bronchiectasis ($2300) [28], systemic lupus erythematosus ($6800) [29], and endometriosis ($9500) [30], but lower than the first-year cost associated with breast cancer ($42,400) [31]. Given the annual incidence of 18.9 GCA cases per 100,000 population in the US [7, 32], the first-year aggregate cost of GCA following diagnosis is estimated to be nearly one billion dollars in the US.…”

Section: Discussionmentioning

confidence: 99%

Estimating the Cost of Illness of Giant Cell Arteritis in the United States

Babigumira

Boudreau

et al. 2017

Rheumatol Ther

View full text Add to dashboard Cite

IntroductionGiant cell arteritis (GCA) is a chronic vasculitis affecting approximately 230,000 Americans. Limited data exist on the healthcare resource utilization and costs attributable to GCA. The objective of this study was to estimate the cost of illness in patients with GCA in the US.MethodsA cohort of patients with a new GCA diagnosis was identified from a large US claims database between 1 January 2008 and 31 December 2012. Newly diagnosed GCA patients were defined by two claims with GCA (ICD-9 446.5) as one of the listed diagnoses during the study period and no GCA diagnosis in the 12 months prior. Subjects without a GCA diagnosis were matched 5:1 to cases. One-year healthcare costs were compared among cases and controls, adjusting for covariates using generalized linear models.ResultsA cohort of 1293 GCA patients and 6465 controls was identified. The mean age was 73 years, and 69% were females. Mean Charlson Comorbidity Index was 1.9 for GCA patients and 1.0 for controls. Mean 1-year cost for GCA patients was $34,065 [standard deviation (SD) $52,411], and mean 1-year cost for controls was $12,890 (SD $37,345). After multivariate adjustment, the difference in 1-year cost between GCA patients and controls was $16,431 (95% CI $13,821–$19,041).ConclusionsPatients with GCA experience substantially higher healthcare costs in the first year following diagnosis compared to patients without GCA. These results add to the limited evidence available to inform researchers, clinicians, and policymakers on the cost burden of GCA in the US.FundingGenentech Inc.

show abstract

“…A more recent report published in 2012, using claims data from 2003–2008, shows that the total health care cost per patient within the first year of BC treatment was $42,401 (equivalent to ~$48,300 in 2012 dollars) 57. The high cost of BC management is due to a number of factors 58.…”

Section: Considerations For Payersmentioning

confidence: 99%

Considerations for payers in managing hormone receptor-positive advanced breast cancer

Chitre

Reimers²

2014

CEOR

View full text Add to dashboard Cite

Breast cancer (BC) is the second most common cause of death in women. In 2010, the direct cost associated with BC care in the US was $16.5 billion, the highest among all cancers. By the year 2020, at the current rates of incidence and survival, the cost is projected to increase to approximately $20 billion. Although endocrine therapies to manage hormone receptor-positive (HR+) BC are highly effective, endocrine resistance results in disease progression. Increased understanding of endocrine resistance and the mechanisms of disease progression has led to development and subsequent approval of novel targeted treatments, resulting in the expansion of the therapeutic armamentarium to combat HR+ BC. Clear guidelines based on the safety and efficacy of treatment options exist; however, the optimal sequence of therapy is unknown, and providers, payers, and other key players in the health care system are tasked with identifying cost-effective and evidence-based treatment strategies that will improve patient outcomes and, in time, help curb the staggering increase in cost associated with BC care. Safety and efficacy are key considerations, but there is also a need to consider the impact of a given therapy on patient quality of life, treatment adherence, and productivity. To minimize cost associated with overall management, cost-effectiveness, and financial burden that the therapy can impose on patients, caregivers and managed care plans are also important considerations. To help evaluate and identify the optimal choice of therapy for patients with HR+ advanced BC, the available data on endocrine therapies and novel agents are discussed, specifically with respect to the safety, efficacy, financial impact on patients and the managed care plan, impact on quality of life and productivity of patients, and improvement in patient medication adherence.

show abstract

Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States

Abstract: Recently diagnosed breast cancer represents a substantial economic burden for US healthcare payers.

Cited by 18 publications

References 15 publications

Medical Care Costs of Breast Cancer in Privately Insured Women Aged 18–44 Years

Medical Care Costs of Breast Cancer in Privately Insured Women Aged 18–44 Years

Estimating the Cost of Illness of Giant Cell Arteritis in the United States

Considerations for payers in managing hormone receptor-positive advanced breast cancer

Contact Info

Product

Resources

About